Resveratrol and endometriosis: In vitro and animal studies and underlying mechanisms (Review)

Biomed Pharmacother. 2017 Jul;91:220-228. doi: 10.1016/j.biopha.2017.04.078. Epub 2017 Apr 28.


Endometriosis is characterized by the existence of endometrial tissue and stroma exterior to the uterus. Despite the high prevalence, the etiology of endometriosis remains elusive. The search for the most promising compounds for treatment of endometriosis has led to the identification of resveratrol. Resveratrol, a plant-derived polyphenolic phytoalexin, demonstrates broad-spectrum health beneficial effects, including anti-proliferative, anti-inflammatory, antineoplastic and antioxidant. Because of these properties and its wide distribution in plants, resveratrol is proposed as a great potential to treat endometriosis. In animal models of endometriosis, resveratrol supplementation has displayed beneficial results as it decreased the number and volume of endometrial implants, suppressed proliferation, vascularization, inflammation, cell survival and increased apoptosis. On the other hand, resveratrol treatment in-vitro studies, reduced invasiveness of endometriotic stromal cells (ESCs) and suppressed their inflammatory responses. In this review, we will summarize the recent studies in in-vitro and animal studies on resveratrol and endometriosis.

Keywords: Animal studies; Endometriosis; In-vitro studies; Resveratrol; Review.

Publication types

  • Review

MeSH terms

  • Animals
  • Biological Availability
  • Endometriosis / drug therapy*
  • Female
  • Humans
  • Inflammation / pathology
  • Oxidative Stress / drug effects
  • Resveratrol
  • Stilbenes / pharmacology
  • Stilbenes / therapeutic use*


  • Stilbenes
  • Resveratrol